Pharmacy benefit programs will clearly see operational and economic changes in 2011, from phasing out the donut hole to growth in specialty pharmacy
PHARMACY BENEFIT PROGRAMS will clearly see operational and economic changes in 2011, from phasing out the donut hole to growth in specialty pharmacy. Likewise, an increase in utilization of chronic-care drugs and a potential plateau in the use of generics are factors driving pharmacy trends next year.
DRUG TREND 2011
He prescribes better management of the total cost of care, more aggressive use of utilization tools, such as prior authorization, and the promotion of preferred drug therapies in certain classes.
Although he anticipates that the gain from generics may lose steam as the opportunities dwindle, Calabrese says there are still some blockbusters yet to come off patent.
On the other hand, specialty pharmacy is on the rise, and costs in that category will dwarf any savings gained from the use of non-specialty generics.
The results of a national survey of more than 120 insurers and administrators, conducted by Buck Consultants, indicate an average prescription drug trend of 11.3%. However, PBMs, who usually do not assume any underwriting risk, report only a 5.8% increase. Harvey Sobel, principal and consulting actuary, Buck Consultants, Secaucus, N.J, says this is the biggest spread he has ever encountered between insurers and PBMs.
He attributes the jump to the new federal excise tax to be imposed on certain manufacturers of branded products based on annual sales starting in 2011, as a result of the reform law.
Calabrese points to the pathway for biosimilars and the phase-out of the Part D donut hole-in which manufacturers will pick up half the costs assumed by beneficiaries-as two additional drivers for 2011.
Judy Cahill, executive director, Academy of Managed Care Pharmacy (AMCP), questions the clarity of the new statute related to the donut hole.
"The statute says that pharma companies will pay 50% of the cost of 'applicable drugs' once a Medicare beneficiary reaches the donut hole; however, CMS has not defined 'applicable drugs,'" she says. "The way a Medicare Part D contractor will find out if it has correctly classified a drug as 'applicable' is only after CMS adjudicates a claim for reimbursement. If CMS determines the medication is not an 'applicable' drug, it will not process the claim and deny payment to the Part D plan."
Buck's Sobel says that the phasing out of the donut hole will place an extra burden on manufacturers, causing them to raise prices.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More